Key takeaway
What This Development Means
The UK government has accepted advice to retain existing synthetic cathinones in Class B and expand the generic definition to selected psychoactive variants currently outside it. The announcement is a policy commitment, not a legal reclassification. Chemical suppliers, pharmaceutical researchers, analytical laboratories and licence holders should monitor the promised draft legislation and verify scope before changing controls.
Have all synthetic cathinones become Class B drugs?
No. Many are already Class B under the existing generic wording, while some named related substances have different classifications. The government intends to add selected variants, but no draft legislation or commencement date has been published, so the proposed expansion is not yet law.
Why did the government not move monkey dust cathinones to Class A?
The Advisory Council recognised serious local harms but found insufficient comparative human evidence to justify Class A and considered that stigma and displacement to more hazardous drugs could worsen outcomes. The government accepted retaining the existing Class B position alongside public-health and enforcement measures.
Source basis: Home Office Response To The ACMD, Letter Dated 7 September 2026 (Published 10 September 2026)
UK Synthetic Cathinones Controls Retain Class B Baseline
The UK government's response to the Advisory Council on the Misuse of Drugs accepts that synthetic cathinones already captured by the statutory generic definition should remain Class B drugs. They also remain in Schedule 1 to the Misuse of Drugs Regulations 2001, reflecting the position that they have no recognised medicinal use.
The 10 September response does not upgrade pyrrolidino-cathinones associated with products described as monkey dust to Class A. The Advisory Council found serious localised harms, particularly in North Staffordshire, but considered the evidence insufficient to show harms greater than other Class B stimulants and judged that reclassification disadvantages outweighed possible benefits.
Generic Definition Will Be Expanded Through Future Legislation
The government also accepted a recommendation to update the Misuse of Drugs Act 1971 generic text so that selected psychoactive cathinones outside the current wording become Class B and Schedule 1 substances. The council identified alpha-D2PV as the compound of current concern and advised wording capable of capturing structurally related compounds where the third carbon in the side chain is incorporated into a phenyl ring.
The existing generic controls, introduced in 2010, cover most cathinones notified in Europe. The council found that 19 of 166 cathinone-type novel psychoactive substances notified between 2008 and 2023 fell outside them. Psychoactive substances outside the Misuse of Drugs Act may already be subject to the Psychoactive Substances Act 2016, but that regime is not the same as Class B control.
The Home Office says consultation with academia and the chemical and pharmaceutical industries identified no legitimate uses for the selected additional compounds. Nevertheless, the final legal definition matters because broad structure-based wording could capture research chemicals or future medicinal candidates unintentionally. The government has not published the draft instrument, commencement date or final substance scope. Its statement that legislation will be brought forward urgently is not an application deadline.
Existing Licensing Duties Apply While New Scope Remains Proposed
Current Class B and Schedule 1 controls continue for substances already captured. Schedule 1 materials may generally be produced, possessed or supplied for research or other special purposes only under an appropriate Home Office controlled-drug licence. Specific medicines such as bupropion are excluded from the cathinone generic wording, while pyrovalerone and diethylpropion have different existing classifications and schedules.
Manufacturers, importers, distributors and laboratories should compare inventories and reference standards with the present generic wording, then repeat that legal mapping when draft legislation appears. Research and pharmaceutical organisations should document legitimate-use cases and assess whether licences, secure storage, recordkeeping or import and export permissions would change.
The analytical insight is that structure-based scheduling is intended to anticipate rapid molecular variation, but it transfers compliance risk to chemical-identity interpretation. Organisations will need defensible structure searches rather than relying only on named-substance lists.
Do not relabel uncontrolled compounds as Class B yet. Preserve the consultation evidence and prepare a structure-based inventory review for the draft instrument.
Related Articles
Japan Adopts Global Framework On Chemicals (GFC) Implementation Plan
Japan has adopted the Global Framework on Chemicals (GFC) implementation plan, impacting chemical management across industries.
Global Panel On Chemicals, Waste And Pollution Established To Guide Future Regulation
UN launches new science-policy panel on chemicals, waste and pollution to inform global regulation and support sound risk management.
Japan Launches National GFC Plan To Overhaul Chemicals Management Across Industries
Japan adopts the Global Framework on Chemicals (GFC) plan to improve chemical safety, creating new obligations and opportunities for industry stakeholders.
